Document Detail


Would wider screening for primary aldosteronism give any health benefits?
MedLine Citation:
PMID:  15362958     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty years ago, Jerome Conn described 'a new clinical syndrome which is designated temporarily as primary aldosteronism' in a young patient with hypertension, severe hypokalaemia and a benign adrenocortical tumour, for whom an adrenalectomy cured both the hypertension and hypokalaemia. His report identified the condition known as aldosterone-producing adenoma, a form of curable hypertension. According to Conn, the prevalence of primary aldosteronism in the hypertensive population referred to his department was 20%, but this estimate was subject to referral bias. Primary aldosteronism has long been considered rare, with an estimated prevalence of 0.5-2% among unselected hypertensive patients. During the past 10 years, however, the apparent prevalence of the condition increased dramatically, up to 30% in some series. Overall, the prevalence of primary aldosteronism in series dealing with at least 100 screened hypertensive patients averaged 6%, with one patient in two harbouring an aldosterone-producing adenoma. This increase in prevalence reflects the fact that hypokalaemic and normokalaemic patients are now screened for primary aldosteronism, with the aldosterone to renin ratio used as a screening tool. The current 'epidemic' of primary aldosteronism raises several questions and concerns.
Authors:
Pierre-Francois Plouin; Xavier Jeunemaitre
Related Documents :
17039108 - Alveolar hemorrhage and pulmonary hypertension in systemic sclerosis: a continuum of sc...
6136158 - Complaints of cold extremities among patients on antihypertensive treatment.
2000898 - Prevalence and association of asteroid hyalosis with systemic diseases.
15167238 - Crouzon syndrome: phenotypic signs and symptoms of the postnatally expressed subtype.
8250008 - Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin...
9385298 - Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-st...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  151     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-11-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  305-8     Citation Subset:  IM    
Affiliation:
Hypertension Unit, Hopital Europeen Georges Pompidou, Paris, France. pierre-francois.plouin@egp.ap-hop.paris.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Hyperaldosteronism / diagnosis*,  epidemiology*
Mass Screening*
Prevalence

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Primary hyperparathyroidism: diagnosis and management in the older individual.
Next Document:  Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients wit...